StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research report sent to investors on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
TTNP opened at $3.34 on Friday. Titan Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $14.80. The company’s fifty day moving average price is $3.67 and its two-hundred day moving average price is $4.83.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Profitably Trade Stocks at 52-Week Highs
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Using the MarketBeat Dividend Tax Calculator
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- What Does Downgrade Mean in Investing?
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
